Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) just unveiled an announcement.
On September 25, 2025, Evaxion A/S announced the out-licensing of its vaccine candidate EVX-B3 to MSD, marking a significant milestone in its strategic partnership. This agreement includes a $7.5 million cash payment to Evaxion, extending its cash runway into the first half of 2027, and potential milestone payments up to $592 million. MSD will assume full responsibility for the development of EVX-B3, while also retaining an option for a second vaccine candidate, EVX-B2, with a decision expected in the first half of 2026. This collaboration not only provides financial benefits but also validates Evaxion’s AI-Immunology™ platform, enhancing its industry positioning and potential for future partnerships.
The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its financial challenges, despite strong revenue growth and positive developments in R&D and partnerships. The technical analysis suggests neutral momentum, while valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with financial stability and strategic progress, but regulatory and market challenges remain significant risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion is a pioneering TechBio company based in Denmark, specializing in AI-Immunology™ powered vaccines. The company leverages artificial intelligence to develop novel immunotherapies for cancer, bacterial diseases, and viral infections, with a focus on addressing high unmet medical needs.
Average Trading Volume: 92,198
Technical Sentiment Signal: Hold
Current Market Cap: $20.84M
For an in-depth examination of EVAX stock, go to TipRanks’ Overview page.